CA-NEXON-AMERICA-INC
5.6.2019 19:32:09 CEST | Business Wire | Press release
World-renowned MMORPG MapleStory announced today its highly anticipated Explorer Bowman class Pathfinder will be available to players on June 26 , with a pre-creation period starting June 12 . In the game’s update following the conclusion of the Black Mage storyline, players can explore the new Adventure Island events, take on a new theme dungeon, and level up faster with new characters via the Tera Burning Project.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190605005050/en/
Pathfinder pre-creation will start on June 12 and will allow players to choose their Pathfinder’s features such as gender, hair color, and more before rolling out their characters for play on June 26. From June 12 to July 23, players will also enjoy the Tera Burning Project , where one new character per account will gain the extraordinary ability to gain a total of three levels each time they level up!
Starting June 12, players can also participate in a number of engaging events in Adventure Island , including Adventure Bingo, Maplerunner, Reverse Battle, and more. Through these events, players can work on their Adventurer Tier and collect Adventure Coins to purchase new items in the Adventure Coin Shop.
The update also brings massive improvements to gameplay systems to help players of all levels. These improvements include refining tutorial and job advancement quests, improving rewards for low level theme dungeons, increasing meso drops in Reboot worlds, as well as lowering quest requirements for 5th Job advancement and improving Star Force success rates and Arcane Symbol improvement costs. Multiple jobs will also be getting skill revamps in order to improve their abilities as well as increase consistency across the various jobs. The new theme dungeon, Secret Forest of Elodin, will also be available for players level 30 to 59 to explore.
Players who visit the Return to Adventure event now through June 10 can earn the Adventure Microsite Gift Box by clicking on the “Get Gifts Now” button on the page. Those who participate in the Return to Adventure event can also receive additional gift boxes with tons of new and exclusive prizes on June 12.
For more details on the MapleStory Pathfinder update, visit http://bit.ly/bw-maplestory-pathfinder .
Assets :
Social Media:
About MapleStory
With 14 years of sustained gaming excellence, MapleStory remains a critically acclaimed classic MMORPG with millions of registered active players around the world. First released in North America in 2005, MapleStory has experienced memorable in-game events, over 274 million created characters, and still is the World’s Largest Online Adventure. For more information about the game, please visit http://maplestory.nexon.net .
About Nexon America Inc. http://www.nexon.net
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO) is a global leader in online games with more than 80 live games operated across more than 190 countries. Nexon America introduced micro-transactions and the free-to-play business model in 2005, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Nexon is listed on the Tokyo Stock Exchange, and the company was placed on the Nikkei Stock Index 300 in 2017.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190605005050/en/
Contact:
Media Contact Wahid Lodin B/HI for Nexon America wahid_lodin@bhimpact.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom